ARTICLE | Clinical News
Clovis' PARP inhibitor leads to PFS of 9.1 months in pancreatic cancer
April 5, 2019 8:25 PM UTC
Clovis reported at AACR that first-line maintenance treatment with Rubraca rucaparib led to a median progression-free survival of 9.1 months from the start of Rubraca therapy among 19 evaluable pancreatic cancer patients in an interim analysis of a Phase II trial.
Clovis Oncology Inc. (NASDAQ:CLVS) said it is evaluating a potential clinical and regulatory path forward for Rubraca in pancreatic cancer and hopes to provide details this year. Rubraca is already approved for ovarian cancer...